I thought it worth reiterating the high level of hypertension (HT) reported in patients treated with Ibruitnib and the potential for serious complications.
In this study reported by Dickerson they looked at 562 consecutive patients treated with ibrutinib for B-cell malignancies from 2009 through 2016, and assessed the new/incident or worsened HTN. They found:
- lymphoid malignancy patients treated with ibrutinib, the subsequent incidence of new hypertension is nearly 72%.
- the development of new or worsened HTN after ibrutinib initiation associates with a more than twofold increased risk of other cardiac events.
The long-term incidence, severity, and impact of HTN development with ibrutinib are unknown.
Read more here: ashpublications.org/blood/a...